5-HT1A Receptor-effector System Responsivity in Panic Disorder

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1992 Jan 1

PMID 1346719

Citations 27

Authors

K P Lesch

M Wiesmann

A Hoh

T Muller

M Osterheider

H M Schulte

Affiliations

Soon will be listed here.

Abstract

To explore 5-HT1A receptor responsivity in panic disorder (PD), hypothermic, neuroendocrine and behavioral responses to the selective partial 5-HT1A receptor agonist ipsapirone (IPS) were investigated in patients with primary PD and healthy controls. Fourteen patients and matched controls received a single oral dose of 0.3 mg/kg IPS or placebo under double-blind, random-assignment conditions. IPS induced hypothermia and corticotropin (ACTH)/cortisol release but had only minimal effects on behavior. Compared with controls, the patients with PD exhibited significantly attenuated thermoregulatory and neuroendocrine responses to IPS. Although the healthy subjects reported increased drowsiness and the PD patients rated themselves more nervous and less calm following administration of IPS, no consistent changes in ratings of anxiety or panic symptoms were recorded. The impaired hypothermic and ACTH/cortisol responses following 5-HT1A receptor activation reflects subsensitivity of both the pre- and post-synaptic 5-HT1A receptor-effector system, thus supporting the hypothesis that a 5-HT1A receptor-related serotonergic dysfunction may be linked to the pathophysiology of PD. Future studies of 5-HT1A receptor-effector complex function in conjunction with assessment of the responsivity of other subtypes (e.g. 5-HT2, 5-HT3) should promote the evaluation of 5-HT system integrity in anxiety disorders and its involvement in anxiolytic drug effects.

Citing Articles

Serotonin-1A receptor, a psychiatric disease risk factor, influences offspring immunity via sex-dependent genetic nurture.

Chen R, Nabila A, Phalke S, Castro D, Gal Toth J, Bergin P iScience. 2022; 25(12):105595.

PMID: 36458257 PMC: 9706704. DOI: 10.1016/j.isci.2022.105595.

Chronic mild stress induces differential depression-like symptoms and c-Fos and 5HT1A protein levels in high-anxiety female Long Evans rats.

Calhoun C, Lattouf C, Lewis V, Barrientos H, Donaldson S Behav Brain Res. 2022; 438:114202.

PMID: 36343695 PMC: 9990717. DOI: 10.1016/j.bbr.2022.114202.

A Systematic Review of Thermosensation and Thermoregulation in Anxiety Disorders.

Fischer S, Haas F, Strahler J Front Physiol. 2021; 12:784943.

PMID: 34938204 PMC: 8685525. DOI: 10.3389/fphys.2021.784943.

Perinatal fluoxetine exposure disrupts the circadian response to a phase-shifting challenge in female rats.

Houwing D, de Waard J, Ramsteijn A, Woelders T, de Boer S, Wams E Psychopharmacology (Berl). 2020; 237(8):2555-2568.

PMID: 32533210 PMC: 7351858. DOI: 10.1007/s00213-020-05556-2.

Hypersensitivity to sertraline in the absence of hippocampal 5-HTR and 5-HTT gene expression changes following paternal corticosterone treatment.

Rawat A, Guo J, Renoir T, Pang T, Hannan A Environ Epigenet. 2018; 4(2):dvy015.

PMID: 30046455 PMC: 6054191. DOI: 10.1093/eep/dvy015.

References

Gilbert F, Brazell C, Tricklebank M, Stahl S . Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol. 1988; 147(3):431-9. DOI: 10.1016/0014-2999(88)90178-1. View

Lesch K, Rupprecht R, Poten B, Muller U, Sohnle K, Fritze J . Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry. 1989; 26(2):203-5. DOI: 10.1016/0006-3223(89)90024-3. View

Kahn R, Wetzler S, van Praag H, Asnis G, Strauman T . Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res. 1988; 25(1):101-4. DOI: 10.1016/0165-1781(88)90163-1. View

Kennett G, Curzon G . Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol. 1988; 94(1):137-47. PMC: 1853919. DOI: 10.1111/j.1476-5381.1988.tb11508.x. View

Hartig P . Molecular biology of 5-HT receptors. Trends Pharmacol Sci. 1989; 10(2):64-9. DOI: 10.1016/0165-6147(89)90080-1. View

Koenig J, Gudelsky G, Meltzer H . Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol. 1987; 137(1):1-8. DOI: 10.1016/0014-2999(87)90175-0. View

den Boer J, Westenberg H, Kamerbeek W, Verhoeven W, Kahn R . Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol. 1987; 2(1):21-32. DOI: 10.1097/00004850-198701000-00002. View

Charney D, Woods S, Goodman W, Heninger G . Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl). 1987; 92(1):14-24. DOI: 10.1007/BF00215473. View

Dillon D, Gorman J, Liebowitz M, Fyer A, Klein D . Measurement of lactate-induced panic and anxiety. Psychiatry Res. 1987; 20(2):97-105. DOI: 10.1016/0165-1781(87)90002-3. View

10.

Lesch K, Hoh A, Wiesmann M, Osterheider M, Schulte H . 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry. 1991; 48(6):540-7. DOI: 10.1001/archpsyc.1991.01810300052007. View

11.

Anderson I, Cowen P, Grahame-Smith D . The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology (Berl). 1990; 100(4):498-503. DOI: 10.1007/BF02244002. View

12.

den Boer J, Westenberg H . Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1988; 3(1):59-74. DOI: 10.1097/00004850-198801000-00005. View

13.

Hamik A, Peroutka S . 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989; 25(5):569-75. DOI: 10.1016/0006-3223(89)90217-5. View

14.

Backus L, Sharp T, Grahame-Smith D . Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol. 1990; 100(4):793-9. PMC: 1917590. DOI: 10.1111/j.1476-5381.1990.tb14094.x. View

15.

Rausch J, Stahl S, Hauger R . Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry. 1990; 28(1):73-8. DOI: 10.1016/0006-3223(90)90434-4. View

16.

Glennon R . Serotonin receptors: clinical implications. Neurosci Biobehav Rev. 1990; 14(1):35-47. DOI: 10.1016/s0149-7634(05)80158-7. View

17.

Zohar J, Mueller E, Insel T, Murphy D . Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987; 44(11):946-51. DOI: 10.1001/archpsyc.1987.01800230026006. View

18.

File S . Interactions of anxiolytic and antidepressant drugs with hormones of the hypothalamic-pituitary-adrenal axis. Pharmacol Ther. 1990; 46(3):357-75. DOI: 10.1016/0163-7258(90)90024-v. View

19.

Hollander E, Fay M, Cohen B, Campeas R, Gorman J, Liebowitz M . Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988; 145(8):1015-7. DOI: 10.1176/ajp.145.8.1015. View

20.

Lesch K, Aulakh C, Tolliver T, Hill J, Murphy D . Regulation of G proteins by chronic antidepressant drug treatment in rat brain: tricyclics but not clorgyline increase Go alpha subunits. Eur J Pharmacol. 1991; 207(4):361-4. DOI: 10.1016/0922-4106(91)90012-7. View